However, certain hurdles continue to keep regenerative therapies from attaining the status quo they deserve. There are still many facets of regenerative medicine that are yet to explore and address. As such, there is a lot of speculation, criticism, fallacy, debate, and, more importantly, optimism around regenerative therapies.
R3 Stem Cell has been at the forefront of performing regenerative therapies for the past decade. With over 16,000 regenerative therapies worldwide, they have never experienced a single significant adverse event. This is indeed a crowning achievement when compared to conventional treatment practices such as surgery and narcotic prescriptions.
“For years, we asked patients if they’d undergo regenerative therapy again or if they’d recommend it to friends and family. On average, 85 percent of our patients say yes. These are people with life-challenging conditions such as arthritis, diabetes or kidney failure, and multiple sclerosis,” prides David Greene, Founder and CEO, R3 Stem Cell. While specifying the types of stem cell treatments that R3 Stem Cell delivers, Greene mentions that they do not offer embryonic stem cell therapies that are obtained from aborted fetuses. The company primarily uses stem cells from donated umbilical cords and amniotic fluid, which are essentially the leftover material after a scheduled C-section.
R3 Stem Cell’s therapies include PRP therapy, umbilical cord stem cell therapy, adipose cell therapy, and exosome therapy. The company is also among the most cost-effective regenerative therapy providers, thanks to its broad presence in the U.S. and abroad, spanning 45 centers.
Greene mentions that in countries like Mexico and Pakistan, they were able to bring the cost of regenerative procedures to less than half of what it costs in the U.S., thereby bringing the therapies to so many more patients.
R3 Stem Cell: Democratizing Regenerative Medicine
R3 Stem Cell’s growth trajectory entails partnering with practices that are looking to leverage regenerative medicine
Going the extra mile, R3 Stem Cell produces engaging content for patients in the form of masterclasses and awareness video that bursts many of the myths and misconceptions around regenerative medicine. The company even showcases interviews with patients before, during, and after they undergo regenerative treatment.
Greene shares a recent recovery story of a stroke patient in Pakistan who faced issues balancing the right side of his body. At only 37 years of age, he couldn’t walk and had to take a break from his desk work every hour as he would feel confused and ‘foggy.’
After receiving a combination of stem cell and exosome therapy from R3 Stem Cell, the patient stopped feeling foggy in a couple of weeks, and within three months, he was able to walk again without the need for assistance. Greene mentions that the patient’s body—that didn’t improve with other medications and treatments—continues to respond to regenerative therapy.
R3 Stem Cell gives a realistic picture to patients regarding the use of regenerative treatments for their conditions, as opposed to providing misleading information like many of the company’s competitors. There may be instances where they’d need to do multiple treatments either periodically or over the course of a specified timeframe. The results may vary and may not guarantee recovery, contrary to widespread misconceptions regarding regenerative therapy. Maintaining utmost transparency and honesty about these aspects while interacting with patients is indicative of the values that R3 Stem Cell upholds.
Someday (soon enough, optimistically speaking), regenerative medicine will manifest as the new paradigm in the healthcare landscape, at which point entities like R3 Stem Cell will be known for being the early torchbearers of the trade.